

Appl. No. : 10/063,514  
Filed : May 1, 2002

#### AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);

~~(b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;~~

~~(b)(e) the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or~~

~~(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;~~

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

2. (Currently Amended) The isolated polypeptide of Claim 1 having at least 85% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);

~~(b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;~~

~~(b)(e) the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or~~

~~(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;~~

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

3. (Currently Amended) The isolated polypeptide of Claim 1 having at least 90% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);

~~(b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;~~

~~(b)(e) the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or~~

~~(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;~~

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

4. (Currently Amended) The isolated polypeptide of Claim 1 having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);

~~(b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;~~

~~(b)(e) the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or~~

Appl. No. : 10/063,514  
Filed : May 1, 2002

(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

5. (Currently Amended) The isolated polypeptide of Claim 1 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);

(b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;

(b)(e) the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or

(d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or

(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

6. (Currently Amended) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);

(b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;

(b)(e) the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or

(d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or

Appl. No. : 10/063,514  
Filed : May 1, 2002

(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922.

7. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10).

8. (Canceled).

9. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the extracellular domain of the polypeptide having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10.

10. (Canceled).

11. (Original) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922.

12. (Original) A chimeric polypeptide comprising a polypeptide according to Claim 1 fused to a heterologous polypeptide.

13. (Original) The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

**Appl. No.** : **10/063,514**  
**Filed** : **May 1, 2002**

**DELETION OF INVENTORS**

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.